Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2008-04-29
2008-04-29
Blanchard, David J. (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387300, C536S023530, C435S320100, C424S130100
Reexamination Certificate
active
11536603
ABSTRACT:
Humanized and variant anti-VEGF antibodies and various uses therefor are disclosed. The anti-VEGF antibodies have strong binding affinities for VEGF; inhibit VEGF-induced proliferation of endothelial cells in vitro; and inhibit tumor growth in vivo.
REFERENCES:
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 5530101 (1996-06-01), Queen et al.
patent: 5580723 (1996-12-01), Wells et al.
patent: 6037454 (2000-03-01), Jardieu et al.
patent: 6054297 (2000-04-01), Carter et al.
patent: 6472585 (2002-10-01), Botstein et al.
patent: 6884879 (2005-04-01), Baca et al.
patent: 7060269 (2006-06-01), Baca et al.
patent: 7169901 (2007-01-01), Baca et al.
patent: 2002/0032315 (2002-03-01), Baca et al.
patent: 0239400 (1994-08-01), None
patent: 0451216 (1996-01-01), None
patent: 451216 (1996-01-01), None
patent: 1 325 932 (2005-04-01), None
patent: 2188638 (1987-10-01), None
patent: 2268744 (1994-12-01), None
patent: 91/00996 (1991-01-01), None
patent: WO 91/09967 (1991-07-01), None
patent: WO 92/18619 (1992-10-01), None
patent: WO 92/22653 (1992-12-01), None
patent: WO 94/04679 (1994-03-01), None
patent: WO 94/10202 (1994-05-01), None
patent: WO 96/30046 (1996-10-01), None
patent: WO 98/45331 (1998-10-01), None
patent: WO 98/45332 (1998-10-01), None
Brown et al., “Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract”Cancer Research53(19):4727-4735 (1993).
Brown et al., “Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer”Human Pathology26(1):86-91 (1995).
Carter et al., “Humanization of an Anti-p185HER2Antibody For Human Cancer Therapy”Proc. Natl. Acad. Sci. USA89(10):4285-4289 (May 1992).
Chang et al., “High-Level Secretion of Human Growth Hormone byEscherichia coli ” Gene55:189-196 (1987).
Chisholm, “High Efficiency Gene Transfer into Mammaliam Cells”DNA Cloning 4. Mammaliam Systemspp. 1-41 (1995).
Chothia et al., “Domain Association in Immunoglobulin Molecules. The Packing of Variable Domains”Journal of Molecular Biology186:651-663 (1985).
Clapp et al., “The 16-kilodalton N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis”Endocrinology133(3):1292-1299 (1993).
Cunningham et al., “Production of an Atrial Natriuretic Peptide Variant that is Specific for Type A Receptor”EMBO Journal13(11):2508-2515 (1994).
de Vries et al., “The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor”Science255:989-991 (1992).
Dvorak et al., “Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis”American Journal of Pathology146(5):1029-1039 (1995).
Eaton et al., “Construction and characterization of an active factor VIII variant lacking the central one-third of the molecule”Biochemistry25:8343-8347 (1986).
Eigenbrot et al., “X-Ray Structures of Fragments From Binding and Nonbinding Versions of a Humanized Anti-CD18 Antibody: Structural Indications of the Key Role of VHResidues 59 to 65”Proteins: Structure, Function, and Genetics18:49-62 (1994).
Eigenbrot et al., “X-Ray Structures of the Antigen-Binding Domains From Three Variants of Humanized Anti-p185HER2Antibody 4D5 and Comparison with Molecular Modeling”J. Mol. Biol.229:969-995 (1993).
Ferrara and Davis-Smyth, “The Biology of Vascular Endothelial Growth Factor”Endocrine Reviews18(1) :4-25 (1997).
Folkman and Shing, “Angiogenesis”Journal of Biological Chemistry267:10931-10934 (1992).
Foote et al., “Antibody Framework Residues Affecting the Conformation of the Hypervariable Loops”J. Mol. Biol.224:487-499 (1992).
Garner, A., “Vascular Diseases”Pathobiology of Ocular Disease. A Dynamic Approach, Garner, A., Klintworth GK Eds., 2nd edition, NY:Marcel Dekker pp. 1625-1710 (1994).
Garrard et al., “Fab assembly and enrichment in a monovalent phage display system”Bio/technology9:1373-1377 (1991).
Good et al., “A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin”Proc. Natl. Acad. Sci. USA87(17):6624-6628 (1990).
Gorman et al., “Transient Production of Proteins Using an Adenovirus Transformed Cell Line”DNA Prot. Eng. Tech.2(1):3-10 (1990).
Graham et al., “Characteristics of a Human Cell Line Transformed by DNA from Human Adenovirus Type 5”J. Gen. Virol.36:59-72 (1977).
Hawkins et al., “Selection of Phage Antibodies by Binding Affinity Mimicking Affinity Maturation”J. Mol. Biol.226:889-896 (1992).
Horak et al., “Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer”Lancet340(8828):1120-1124 (1992).
Kabat et al.Sequences of Proteins of Immunological Interest, U.S. Dept. of Health and Human Services, NIH, 5th edition vol. 1:103-108, 324-331 (1991).
Karlsson et al., “Kinetic analysis of monoclonal antibody-antigen interactions with a new biosensor based analytical system”J. Immun. Methods145:229-240 (1991).
Karlsson et al., “Kinetic and Concentration Analysis Using BIA Technology”Methods: A Comparison to Methods in Enzymology6:99-110 (1994).
Kettleborough et al., “Humanization of a Mouse Monoclonal Antibody by CDR-grafting: the Importance of Framework Residues on Loop Conformation”Protein Engineering4(7):773-783 (1991).
Kim et al., “Inhibition of Vascular Endothelial Growth Factor-Induced Angiogenesis Suppresses Tumour Growth in vivo”Nature362:841-844 (Apr. 29, 1993).
Kim et al., “The Vascular Endothelial Growth Factor Proteins: Identification of Biologically Relevant Regions by Neutralizing Monoclonal Antibodies”Growth Factors7(1):53-64 (1992).
Klagebrun and D'Amore, “Regulators of angiogenesis”Ann. Rev. Physiol.53:217-239 (1991).
Kunkel et al., “Efficient site-directed mutagenesis using uracil-containing DNA”Methods in Enzymology204:125-139 (1991).
Kunkel, T., “Rapid and Efficient Site-Specific Mutagenesis Without Phenotypic Selection”Proc. Natl. Acad. Sci.82:488-492 (1985).
Leung et al., “Vascular Endothelial Growth Factor is a Secreted Angiogenic Mitogen”Science246:1306-1309 (Dec. 1989).
Lopez et al., “Transfifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes”Invest. Ophthalmol. Vis. Sci.37(5):855-868 (1996).
Lowman et al., “Selecting High-Affinity Binding Proteins by Monovalent Phage Display”Biochemistry30(45):10832-10838 (1991).
Lucas, et al., “High-Level Production of Recombinant Proteins in CHO Cells Using a Dicistronic DHFR Intron Expression Vector”Nucleic Acids Research24(9):1774-1779 (1996).
Macchiarini et al., “Relation of neovascularisation to metastasis of non-small-cell lung cancer”Lancet340(8812):145-146 (1992).
Mattern et al., “Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma”Brit. J. Cancer73(7):931-934 (1996).
Melnyk et al., “Vascular endothelial growth factor promotes tumor dissemination by a mechanism distinct from its effect on primary tumor growth”Cancer Research56(4):921-924 (Feb. 15, 1996).
Novotny et al., “Structural invariants of antigen binding: comparison of immunoglobulin VL-VHand VL-VLdomain dimers”Proc. Natl. Acad. Sci. USA82(14):4592-4596 (Jul. 1985).
O'Reilly et al., “Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma”Cell79(2)
Baca Manuel
Chen Yvonne Man-Yee
Lowman Henry B.
Presta Leonard G.
Wells James A.
Blanchard David J.
Genentech Inc.
Kalinowski Grant
Tungaturthi Parithosh K.
LandOfFree
Anti-VEGF antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-VEGF antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-VEGF antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3948503